Year-end Sale % OFF 
Abstract
ABSRACTBackgroundSeveral studies have investigated the associations between the podocalyxin-like protein (PODXL) expression quantity or locations and cancers survival, but the results were far from conclusive. Therefore, we proceeded a meta-analysis on PODXL in various human cancers to find its prognostic value and followed confirmation using the TCGA datasets.MethodsWe performed a systematic search, and 18 citations, including 5705 patients were pooled in meta-analysis. The results were verified with TCGA datasets.ResultsTotal eligible studies comprised 5705 patients with 10 types of cancer. And the result indicated that PODXL high-expression or membrane-expression were significantly related to poor overall survival (OS). However, subgroup analysis showed a significant association between high expressed PODXL and poor OS in the colorectal cancer, pancreatic cancer, urothelial bladder cancer, renal cell carcinoma and glioblastoma multiforme. Then, we validated the inference using TCGA datasets, and the consistent results were demonstrated in patients with pancreatic cancer, glioblastoma multiforme, gastric cancer, esophageal cancer and lung adenocarcinoma.ConclusionThe result of meta-analysis showed that high expressed PODXL was significantly linked with poor OS in pancreatic cancer and glioblastoma multiforme, but not in gastric cancer, esophageal cancer or lung adenocarcinoma. And the membrane expression of PODXL might also associate with poor OS. PODXL may act as tumor promotor and may serve as a potential target for antitumor therapy.
Highlights
Several studies have investigated the associations between the podocalyxin-like protein (PODXL) expression quantity or locations and cancers survival, but the results were far from conclusive
We validated the inference using The Cancer Genome Atlas (TCGA) datasets, and the consistent results were demonstrated in patients with pancreatic cancer, glioblastoma multiforme, gastric cancer, esophageal cancer and lung adenocarcinoma
The result of meta-analysis showed that high expressed Podocalyxin-like protein (PODXL) was significantly linked with poor overall survival (OS) in pancreatic cancer and glioblastoma multiforme, but not in gastric cancer, esophageal cancer or lung adenocarcinoma
Summary
Several studies have investigated the associations between the podocalyxin-like protein (PODXL) expression quantity or locations and cancers survival, but the results were far from conclusive. Podocalyxin-like protein (PODXL) is a highly glycosylated type I transmembrane protein associated with CD34 [2,3,4]. PODXL is encoded on chromosome 7q32-q33, and highly expressed by glomerular podocytes, vascular endothelium, hematopoietic cells and breast epithelial. He et al BMC Cancer (2020) 20:620 cells [6,7,8], which involved in many physiologic processes, such as hematopoiesis [9], leucocyte-endothelial cell interaction [10], regulating vascular permeability [11] and neural development [12]. The later findings proved that, PODXL associates with advanced tumor phenotype in some cancers, including breast cancer [1, 13], colorectal cancer [5, 14,15,16], esophageal cancer [17], gastric cancer [17,18,19], glioblastoma multiforme [20], lung adenocarcinoma [21], oral squamous cell carcinoma [4, 22], ovarian cancer [23], pancreatic cancer [24,25,26,27], prostate cancer [28, 29], renal cell carcinoma [30], urothelial bladder cancer [31], and so on
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
